Combination of quinupristin-dalfopristin (synercid) and rifampin is highly synergistic in experimental Staphylococcus aureus joint prosthesis infection

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 4, 2002, Pages 1122-1124

  Saleh Mghir, Azzam ^a   Ameur, Nourdine ^a   Muller Serieys, Claudette ^a   Ismael, Farid ^a   Lemaitre, Françoise ^a   Massias, Laurent ^a   Feger, Céline ^a   Bléton, Rémy ^a   Crémieux, Anne Claude ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DALFOPRISTIN PLUS QUINUPRISTIN; RIFAMPICIN; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COUNT; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; EXPERIMENTAL INFECTION; GRAFT INFECTION; JOINT PROSTHESIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PRIORITY JOURNAL; RABBIT; STAPHYLOCOCCUS INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTITUBERCULAR; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; JOINT PROSTHESIS; METHICILLIN RESISTANCE; PROSTHESIS-RELATED INFECTIONS; RABBITS; RIFAMPIN; STAPHYLOCOCCAL INFECTIONS; TISSUE DISTRIBUTION; VANCOMYCIN; VIRGINIAMYCIN;

EID: 0036208004     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.4.1122-1124.2002     Document Type: Article

References (32)

1. Characterization of mutations in the rpoB gene that confer rifampin resistance in Staphylococcus aureus
2. A new model of experimental prosthetic joint infection due to methicillin-resistant Staphylococcus aureus: A microbiologic, histopathologic, and magnetic resonance imaging characterization
3. Prosthetic osteomyelitis with special reference to the knee: Risks, treatment and costs
4. Analysis of 42 cases of septicemia caused by an epidemic strain of methicillin-resistant Staphylococcus aureus: Evidence of resistance to vancomycin
5. Successful therapy of experiment chronic foreign-body infection due to methicillin-resistant Staphylococcus aureus by antimicrobial combinations
6. 14C]sparfloxacin in an experimental Staphylococcus aureus joint prosthesis infection
7. Evaluation of in vitro activity of quinupristin/dalfopristin and comparator antimicrobial agents against worldwide clinical trial and other laboratory isolates
8. Rifampin resistance. Development during the therapy of methicillin-resistant Staphylococcus aureus infection
9. Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant methicillin-resistant Staphylococcus aureus with RP 59500
10. Critical influence of resistance to streptogramin B-type antibiotics on activity of RP 59500 (quinupristin-dalfopristin) in experimental endocarditis due to Staphylococcus aureus
11. Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY Antimicrobial Surveillance Program, 1997 and 1998
12. Wound infection in hip and knee arthroplasty
13. The effects of exposure at constant (1 h) or exponentially decreasing concentrations of quinupristin/dalfopristin on biofilms of gram-positive bacteria
14. Oral antimicrobial therapy for osteomyelitis
15. Treatment options for infected knee arthroplasties
16. Methicillin-resistant Staphylococcus epidermidis in infection of hip arthroplasties
17. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid®) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada
18. Treatment of experimental staphylococcal infections: Effect of rifampin alone and in combination on development of rifampin resistance
19. Lessons learned from animal models of osteomyelitis
20. Evaluation of new anti-infection drugs for the treatment of infection of prosthetic hip joint
21. Treatment of experimental chronic osteomyelitis due to Staphylococcus aureus with teicoplanin
22. The threat of vancomycin resistance
23. Bacterial pathogens isolated from patients with bloodstream infection: Frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997)
24. 14C]teicoplanin in experimental Staphylococcus aureus infection of joint prostheses
25. Emergence of vancomycin resistance in Staphylococcus aureus
26. Antimicrobial treatment of orthopedic implant-related infections with rifampin combinations
27. Chemotherapy for gram-positive nosocomial sepsis
28. Perioperative factors associated with septic arthritis after arthroplasty. Prospective multicenter study of 362 knee and 2,651 hip operations
29. Activities of the combination of quinupristin-dalfopristin with rifampin in vitro and in experimental endocarditis due to Staphylococcus aureus strains with various phenotypes of resistance to macrolides-lincosamide-streptogramin antibiotics
30. Role of rifampin for treatment of orthopedic implant-related Staphylococcus aureus: A randomized controlled trial
31. Microbiological tests to predict treatment outcome in experimental device-related infections due to Staphylococcus aureus